BioCentury
ARTICLE | Clinical News

MM-121: Completed Phase II enrollment

October 7, 2013 7:00 AM UTC

Merrimack completed enrollment of 100 patients with triple-negative breast cancer (TNBC) in the second of 2 cohorts in an open-label, U.S. Phase II trial comparing weekly IV MM-121 plus paclitaxel vs....